Search

everythinglearnresearchcommunity

for

Search:↓

The user reported tiny hair growth in thinning areas and improved thickness after 56 days of using 1 mg oral finasteride, 2.5 mg oral minoxidil, and a serum with Redensyl, Anagain, Capixyl, and Procapil. They also take supplements and maintain a healthy lifestyle with no noticeable side effects.

In the US, Amazon Pharmacy offers unlimited generic Finasteride and Dutasteride for $5/month with RxPass, requiring an Amazon Prime membership and a prescription. Alternatives include Costco and other pharmacies, but prices and availability vary.

The user has been using dutasteride, oral minoxidil, and vitamin D for 8 months with no improvement in hair loss. They are considering trying RU58841 or a hair transplant due to the ineffectiveness of current treatments.

A new trial for Verteporfin to treat hair loss will start in LA, led by Dr. Behnam. Users are hopeful it could be a breakthrough treatment.

User started hair loss treatment 6 months ago using 0.5mg dutasteride, 5mg oral minoxidil, 80mg RU58841, and microneedling 1.5mm every other week. They experienced significant hair regrowth and no side effects, with others encouraging continued progress.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.

The conversation is about a user whose insurance switched their prescription from finasteride to dutasteride, and they are considering whether to appeal the decision or continue with dutasteride. Other users suggest that both medications are affordable without insurance and that dutasteride may be more effective long-term.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

RU58841 and Minoxidil can cause heart-related side effects like chest pain and heart racing. Pyrilutamide is suggested as a safer alternative, though it's new and costly.

The user is experiencing aggressive diffuse thinning despite using 1mg oral finasteride daily, topical minoxidil twice, microneedling, and Nizoral for seborrheic dermatitis. They are considering switching to dutasteride or RU58841 but are advised to seek a second opinion to determine the cause of hair loss.

The user started using topical minoxidil 5% and ketoconazole shampoo for hair loss, noticing minimal progress after three months, with fine hairs appearing. They experienced a setback when reducing the application to once a day but resumed twice daily applications.

The conversation discusses whether Pyrilutamide from Koshine is different from Anageninc and if it's effective for hair loss. It also questions if sticking to RU58841 would be better.

The user has not seen results from various hair loss treatments including finasteride, dutasteride, minoxidil, and others over several years and is considering adding RU58841 and starting hormone replacement therapy. They are also experiencing anxiety and contemplating moving to a more accepting environment for their nonbinary identity.

The user experienced hair recovery using oral dutasteride 0.5 mg and oral minoxidil 5 mg daily, considering increasing dutasteride dosage but concerned about cost and effectiveness. They noted progress and discussed alternatives like hair transplants and other medications.

The user stopped oral minoxidil due to side effects and is now using dutasteride mesotherapy and plans to start oral dutasteride. They are concerned about potential hair shedding and wonder if dutasteride alone will be effective.

Switching from finasteride to dutasteride led to significant hair regrowth and thickening for the user, who also uses ketoconazole shampoo. The user experienced increased libido and encourages others not to be discouraged by negative opinions about dutasteride.

The user experienced worsening hair thinning despite using finasteride, minoxidil, and ketoconazole shampoo, and switched to dutasteride five months ago. They are considering adding tretinoin and microneedling to their routine for better results.

Veradermics is a promising new treatment for hair loss, essentially a repackaged version of Minoxidil. The user is optimistic about its potential effectiveness.

This user has conducted data scraping of 365 Reddit posts on the hairloss drug Pyrilutamide over the last year to analyse efficacy and side effects. The findings, which are available in a 19 page report with graphs, suggest that 22% of Pyrilutamide users experience positive results while 63% experience symptoms. A larger analytics project is proposed for other drugs with enough demand.

A dutasteride simulator predicts that daily 0.5 mg dosing results in higher DHT suppression compared to less frequent dosing. Twice-weekly dutasteride may be as effective as finasteride 5 mg, providing a balance between efficacy and ease of use.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.

The user experienced decreased libido with saw palmetto and is now considering topical anti-androgens like RU58841, pyrilutamide, and topical dutasteride for hair loss. Minoxidil is also mentioned as a potential addition, but the user is cautious about side effects and availability of treatments.

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.